


# Medical Research: It's About Michael



**“Only months earlier, I had been a typical healthy American male in his 20’s. Suddenly there was a 50% chance that I would never live to see my 30<sup>th</sup> birthday.”**

By the time Michael Moskowitz was diagnosed with non-Hodgkin’s lymphoma, he had a golf ball-sized tumor in his abdomen and one as big as a fist in his chest. The cancer was so aggressive that eating, speaking, and breathing became difficult, and he was given only a 50% chance of surviving more than a few weeks. In a last-ditch effort, he was treated with the drug Rituxan, along with chemotherapy, and miraculously went into remission. After he recovered, Michael went on to receive his law degree in health law and policy, spent time working as a law clerk for the American Cancer Society ([www.cancer.org](http://www.cancer.org)), and is currently practicing law.



According to a study published in the journal *Blood*, between 1998 (the year after it was approved by the FDA) and 2013, the drug Rituxan has saved a cumulative 289,793 years of life across the three major types of cancer it is used to treat<sup>1</sup>. Research funded by the National Cancer Institute, combined with private sector research and development, made this drug possible.

**Over 310,000 American men will die from some form of cancer this year. Since 1991, medical research has saved 952,700 men from dying of these cancers.**

**We’ve made progress. But the funding to sustain it is eroding.**

**Congress: harness your compassion, gather your will, and fund the National Institutes of Health at \$32 billion in FY15.**

**Do it for Michael.**